We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.06%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
+$16.3M
(+0.99%)
Cap. Flow
-$44.8M
Cap. Flow
% of AUM
-2.69%
Top 10 Holdings %
Top 10 Hldgs %
48.94%
Holding
82
New
33
Increased
12
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$73.8M |
| 2 |
Viatris
VTRS
|
+$64.3M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$63M |
| 4 |
Merck
MRK
|
+$56.2M |
| 5 |
ENDP
Endo International plc
ENDP
|
+$53.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARTC
ARTHROCARE CORP
ARTC
|
+$95.6M |
| 2 |
AGN
Allergan Inc
AGN
|
+$94.5M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$68.8M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$50.3M |
| 5 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$50.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.49% |
| 2 | Financials | 4.97% |
| 3 | Technology | 1.5% |
| 4 | Consumer Staples | 0% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Icon
ICLR
$12.6B
| $20.7M | 1.24% |
+434,400
| New | +$19.4M |
|
27
Acadia Pharmaceuticals
ACAD
$4.43B
| $17M | 1.02% |
+700,000
| New | +$17.7M |
|
28
Brookdale Senior Living
BKD
$3.49B
| $16.8M | 1.01% |
+500,000
| New | +$15.1M |
|
|
AMRI
29
DELISTED
Albany Molecular Research Inc
AMRI
| $16.7M | 1.01% |
+900,000
| New | +$12.4M |
|
|
PCYC
30
PUT
DELISTED
PHARMACYCLICS INC
PCYC
| $15M | 0.9% |
+150,000
| New | +$19.5M |
|
|
RGLS
31
DELISTED
Regulus Therapeutics
RGLS
| $14.2M | 0.85% |
13,125
-1,458
| -10% | -$1.62M |
|
32
Centene
CNC
$30.7B
| $14M | 0.84% |
+900,000
| New | +$13.9M |
|
|
AEGR
33
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
| $13.9M | 0.83% |
+300,000
| New | +$17.6M |
|
34
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
| $13.4M | 0.81% |
+200,000
| New | +$15.5M |
|
|
AGN
35
DELISTED
Allergan plc
AGN
| $12.5M | 0.75% |
60,700
+33,800
| +126% | +$6.7M |
|
|
INFI
36
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $12.5M | 0.75% |
+1,050,000
| New | +$14.1M |
|
37
Pfizer
PFE
$143B
| $9.64M | 0.58% |
+316,200
| New | +$9.43M |
|
|
DVAX
38
DELISTED
Dynavax Technologies
DVAX
| $8.67M | 0.52% |
479,498
-1,520,502
| -76% | -$28.2M |
|
39
Tenax Therapeutics
TENX
$363M
| $8.32M | 0.5% |
+47
| New | +$9.3M |
|
|
FPRX
40
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $8.2M | 0.49% |
416,944
-783,056
| -65% | -$13.3M |
|
41
CALL
Exelixis
EXEL
$13.3B
| $7.96M | 0.48% |
+2,250,000
| New | +$15.3M |
|
42
Arrowhead Research
ARWR
$11.9B
| $7.39M | 0.44% |
+450,000
| New | +$7.9M |
|
|
VXRT
43
DELISTED
Vaxart
VXRT
| $7.03M | 0.42% |
+104,545
| New | +$6.47M |
|
|
ESRX
44
DELISTED
Express Scripts Holding Company
ESRX
| $6.91M | 0.42% |
+92,000
| New | +$6.89M |
|
45
Becton Dickinson
BDX
$45.6B
| $6.3M | 0.38% |
+55,145
| New | +$6.06M |
|
|
AGN
46
DELISTED
Allergan Inc
AGN
| $6.02M | 0.36% |
48,500
-776,500
| -94% | -$94.5M |
|
|
SGMO
47
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $5.42M | 0.33% |
+300,000
| New | +$5.78M |
|
48
Novavax
NVAX
$1.2B
| $5.06M | 0.3% |
55,812
-174,188
| -76% | -$19.5M |
|
|
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.56M | 0.27% |
+3,286
| New | +$3.82M |
|
50
Abbott
ABT
$183B
| $3.81M | 0.23% |
99,000
-18,300
| -16% | -$705K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2014 Portfolio in Review
As of Q1 2014, HealthCor Management held 82 positions worth $1.66B, up 0.99% from $1.65B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
HealthCor Management's Q1 2014 filing shows 33 new, 12 increased, 12 reduced and 25 closed positions. Its largest new stake was MEDIVATION, INC.: 2,000,000 shares worth $64.4M. The largest sale was ARTHROCARE CORP, an estimated $95.6M.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 60% a quarter earlier, followed by Financials and Technology.
- HealthCor Management's largest Q1 2014 buy was MEDIVATION, INC.: 2,000,000 shares worth $64.4M.
- HealthCor Management added most to Viatris in Q1 2014, an estimated $64.3M increase.
- HealthCor Management's biggest Q1 2014 reduction was Allergan Inc, cutting an estimated $94.5M.
- HealthCor Management fully exited ARTHROCARE CORP in Q1 2014, selling an estimated $95.6M.
- HealthCor Management's ten largest holdings make up 49% of its $1.66B portfolio in Q1 2014.
- HealthCor Management opened 33 new positions and closed 25 in Q1 2014.
- HealthCor Management's portfolio value rose 0.99% quarter-over-quarter to $1.66B.
Based on HealthCor Management's 13F filing for Q1 2014, filed 15 May 2014.